Disitamab Vedotin combined with Toripalimab

Phase 2Antibody–drug conjugate

FFujian Medical University Union Hospital

Disitamab Vedotin combined with Toripalimab is one of 4 small molecule programs targeting Extramammary Paget Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Extramammary Paget DiseaseActive, not recruiting

Extramammary Paget DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Extramammary Paget Disease

#DrugCompanyPhaseTrials

Aldara

BBausch Health Americas, Inc.

Xylocaine

Tylenol

Disitamab Vedotin combined with Toripalimab

FFujian Medical University Union Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Extramammary Paget Disease

NCT06791070

Clinical

Trials by Indication[1]

Extramammary Paget Disease1 trial

A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum

Recruiting·FFujian Medical University Union Hospital·Phase 2·NCT06791070·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Disitamab Vedotin combined with Toripalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Disitamab Vedotin combined with Toripalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Disitamab Vedotin combined with Toripalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Medical University Union Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: FFujian Medical University Union Hospital

Disitamab Vedotin combined with Toripalimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Extramammary Paget Disease1 trial

References

Drug Info

Quick Facts

Related News